Business · 15/11/20261 min read
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026
Summary
VENTURE Analysis Finds 74% of Participants Receiving Subcutaneous VK2735 Improved by at Least One BMI Category after 13 Weeks VK2735 Treatment Led to Improvement Across Multiple Cardiometabolic Markers SAN DIEGO, Nov. 15, 2026 — Viking Therapeutics, Inc. (Viking) (NASDAQ:...
Original source language: PR Newswire — Global News ReleasesOpen original release →